Iberdomide combined with daratumumab and dexamethasone shows promising results in improving MRD negativity rates for relapsed multiple myeloma patients.
Sabrina Serani
Sabrina Serani is the assistant managing editor for Targeted Oncology.
Articles by Sabrina Serani
IMNN-001 shows promising results in enhancing the tumor microenvironment and improving survival rates in advanced ovarian cancer treatment.
FDA prioritizes review of T-DXd for first-line HER2-positive breast cancer treatment, showcasing significant survival benefits in recent studies.
Discover the latest advancements in lymphoma treatment, including innovative therapies and personalized medicine, enhancing patient outcomes and quality of life.
The evERA study reveals promising results for giredestrant in treating advanced ER-positive breast cancer, enhancing progression-free survival for patients.
Research explores innovative treatments for high-risk smoldering multiple myeloma, highlighting promising results from the bispecific antibody linvoseltamab.
The FDA approves a new diagnostic kit for identifying acute leukemia patients eligible for the groundbreaking Menin inhibitor, revumenib.
New NCCN guidelines recommend lurbinectedin with atezolizumab as a first-line maintenance therapy for extensive-stage small cell lung cancer, enhancing treatment options.
Dr Daniel Petrylak discusses groundbreaking advancements in prostate cancer treatment, including genetic mutations, PARP inhibitors, and innovative PROTAC therapies.
MNV-201 gains FDA fast track designation for myelodysplastic syndromes, promising expedited development and potential breakthroughs in treatment.
A new treatment combination shows promise in extending progression-free survival for advanced prostate cancer patients, highlighting innovative cancer therapies.
New study reveals plixorafenib shows significant clinical benefits for thyroid cancer patients with BRAF mutations, offering hope for targeted therapies.
The FDA approved Bosaya and Aukelso biosimilars, enhancing options for cancer-related bone loss, including in patients with multiple myeloma.
The FDA fast-tracks CRB-701, an innovative ADC for advanced head and neck cancer, showing promising efficacy and safety in ongoing trials.
Ligufalimab receives FDA orphan drug designation for AML, showcasing promising efficacy and safety in treating hematologic malignancies and solid tumors.
Researchers explore innovative macrocyclic peptides to target small cell lung cancer, revealing promising therapeutic strategies for this aggressive disease.
FDA designates raludotatug deruxtecan as a breakthrough therapy for treating platinum-resistant ovarian cancers, enhancing patient care options.
Zipalertinib demonstrates significant efficacy and manageable safety in treating EGFR exon 20 insertion–mutated NSCLC, offering hope for patients.
Dordaviprone gains NCCN approval as a promising treatment for recurrent H3 K27M-mutant diffuse glioma, addressing urgent patient needs.
Promising results emerge from a clinical trial combining IDE397 and sacituzumab govitecan for treating MTAP-deleted urothelial cancer, showcasing safety and efficacy.
FDA accepts relacorilant and nab-paclitaxel for platinum-resistant ovarian cancer, showing promising survival benefits in recent trials.
FDA fast tracks GLSI-100 for HER2-positive breast cancer, promising new hope for patients with unmet medical needs. Discover its potential benefits.
The FDA approves selumetinib for young patients with neurofibromatosis type 1, offering hope for effective treatment of inoperable tumors.
The FDA approves Inlexzo, a groundbreaking treatment for bladder cancer, offering hope for patients unresponsive to traditional therapies.
FDA designates olomorasib and pembrolizumab as breakthrough therapy for advanced KRAS G12C-mutant lung cancer, showing promising response rates in trials.
FDA grants orphan drug designation to BA-101, a promising treatment for glioblastoma, aiming to improve outcomes in this challenging cancer.
Myeloma research faces funding uncertainties, yet collaboration and innovation drive optimism for breakthroughs in treatment and patient care.
New data highlightstaletrectinib's impressive efficacy and safety in treating ROS1-positive non–small cell lung cancer, offering hope for patients.
Interim results from the CAReS trial highlight ART27.13's potential to combat cancer-related weight loss, offering hope for effective treatment in CACS.
Pirtobrutinib shows significant promise in improving progression-free survival for patients with treatment-naive CLL/SLL, challenging traditional therapies.